Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 10/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730163 | 0.92 | PTGS1 (0.40) | FEN1ALOX5APPTGS1PTGS2LRRK2 | |
| SCHEMBL7045240 | 0.90 | NR1H2 (0.44) | FEN1ALOX5APPTGS1PTGS2SCN5A | |
| SCHEMBL6725390 | 0.89 | PTGS2 (0.45) | FEN1ALOX5APPTGS1PTGS2 | |
| SCHEMBL6745117 | 0.88 | ALOX5AP (0.40) | FEN1ALOX5APPTGS1PTGS2LRRK2 | |
| SCHEMBL6746250 | 0.88 | FEN1 (0.39) | FEN1ALOX5APPTGS1PTGS2LRRK2 | |
| SCHEMBL6729554 | 0.88 | PTGS2 (0.48) | FEN1ALOX5APPTGS1PTGS2 | |
| SCHEMBL6723355 | 0.86 | PTGS2 (0.42) | FEN1ALOX5APPTGS1PTGS2 | |
| SCHEMBL6725930 | 0.85 | PTGS2 (0.48) | FEN1ALOX5APPTGS1PTGS2 | |
| SCHEMBL7048299 | 0.85 | PTGS2 (0.51) | FEN1ALOX5APPTGS1PTGS2 | |
| SCHEMBL6723491 | 0.85 | PTGS1 (0.39) | FEN1ALOX5APPTGS1PTGS2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | FEN1 1649/4885ALOX5AP 454/4885PTGS1 4/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | FEN1 1713/4885ALOX5AP 395/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.